Cornelia L. Dekker, M.D.
Academic Appointments
- Professor (Research), Pediatrics - Infectious Diseases
- Member, Child Health Research Institute
Key Documents
Contact Information
-
Clinical Offices
Pediatric Infectious Diseases 300 Pasteur Dr G312 MC 5208 Stanford, CA 94305 Tel Work (650) 724-4437 Fax (650) 725-8153Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 724-4437Alternate Contact Nancy Greguras Administrative Associate Email Tel Work (650) 498-6227Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Pediatric Infectious Disease
- Vaccine Clinical Trials
- Vaccine Safety
- Infectious Diseases, Pediatric
Administrative Appointments
- Medical Director, Stanford-LPCH Vaccine Program (1999 - present)
- Member, HIV Vaccine Trial Network Safety Monitoring Board (2009 - present)
- IRB Reviewer, Stanford Administrative Panel on Human Subjects in Medical Research, Panel 3 (2002 - present)
- Member, Stanford GCRC Advisory Committee (2006 - present)
- Member, NVAC Vaccine Safety Working Group (2008 - 2011)
- Member, National Vaccine Advisory Committee (NVAC) (2005 - 2010)
Honors and Awards
- Junior Faculty Award, SmithKlein Beecham (07/05/00-07/04/02)
- Excellence in Teaching, Stanford Univ. School of Medicine (06/23/08)
Professional Education
| Fellowship: | Duke University Medical Center NC (1982) |
| Residency: | Duke University Medical Center NC (1979) |
| Board Certification: | General Pediatrics, American Board of Pediatrics (1981) |
| Internship: | Duke University Medical Center NC (1977) |
| Medical Education: | Michigan State University MI (1976) |
| B.S.: | Michigan State University, Microbiology & Public Health, Human Clinical Medicine (1973) |
Graduate & Fellowship Program Affiliations
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
The overarching theme of our research activities is human response to natural virus infection and to vaccines. We have conducted several studies of adult, toddler and infant immune response to initial infection with human cytomegalovirus (HCMV). Our latest was a project in which we screened 20,000 newborn infants at Stanford, El Camino and Santa Clara Valley Hospitals for evidence of congenital HCMV infection. Those infants identified as being infected were enrolled into a 3-year prospective study for medical, audiology and immunology screening. The hearing screening portion is designed to identify, as early as possible, infants who develop sensorineural hearing loss as a result of this infection.
A second area of clinical research is supported by Dr. Mark Davis' NIH-funded U19 project entitled "Protective Mechanisms Against Pandemic Respiratory Virus" and the newer U19 project entitled "Vaccination and Infection: Indicators of Immunological Health and Responsiveness". To provide samples for the lab projects we immunize children and adults (including elderly) with one of four different, licensed influenza vaccines (TIV, TIV high-dose, TIV Intradermal or LAIV) to study in detail the immune response to immunization. Blood samples collected from study subjects are analyzed for influenza-specific B and T-cell responses as well as gene expression studies and cytokine analyses. Our latest studies have focussed on genetic aspects by enrolling fraternal and identical twins. Under the new U19, we are conducting a study of the shingles vaccine in twins and non-twin adults for a close examination of T-cell responses.
Our group also is funded as part of the Vaccine Treatment and Evaluation Units by NIH through our collaborators at Vanderbilt University. We have conducted studies of avian, novel H1N1 and seasonal influenza vaccines and a new malaria vaccine.
A fourth area of interest is vaccine safety. Stanford is one of six designated Centers for Immunization Safety Assessment (CISA) sponsored by the CDC. The network provides consultation to CDC on evaluation and treatment of adverse events following immunization with licensed vaccines, develops protocols to study certain events that occur following immunization (including hypersensitivity reactions, safety of live viral vaccines in immunodeficient children, genetics study of Guillain-Barre syndrome patients). We also collaborate with Dr. Greg Enns on a study of the safety of influenza vaccine and its metabolic effects in patients with the MELAS mtDNA polymorphisms.
For further information about ongoing studies, please refer to our website at http://vaccines.stanford.edu.
Clinical Trials
- Not Recruiting Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages
- Not Recruiting Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations
- Not Recruiting Adenovirus Vaccine for Malaria
- Recruiting Seasonal Influenza HA DNA (VRC) With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults Ages 18-70 Years
Publications
- Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol. 2013: 659
- Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination. Pediatr Infect Dis J. 2013; (2): 163-8
- Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. J Infect Dis. 2013; (2): 288-96
- Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med. 2013; (171): 171ra19
- Algorithm to assess causality after individual adverse events following immunizations. Vaccine. 2012; (39): 5791-8
- Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis. 2012; (6): 811-20
Help